ERBB2 and breast carcinoma: Combining HER2-directed ADCs and immunotherapy was trialled in the phase II KATE2 study, where T-DM1 and atezolizumab were compared to T-DM1 and placebo in pre-treated patients with HER-2-positive breast cancer.